Taurolidine is an antimicrobial that is used to prevent infections in catheters. Side effects and the induction of bacterial resistance is uncommon. It is also being studied as a treatment for cancer. It is derived from the endogenous amino acid derivati + some more technical info. Taurolidine is a synthetically modified taurine derivative that exerts broad spectrum antimicrobial and anti-endotoxin activity through the release of reactive methylol species that chemically modify bacterial cell surface structures and microbial toxins, disrupting cell wall integrity and inhibiting biofilm formation. In clinical practice it is most often formulated as a catheter lock solution where it is instilled into the catheter lumen and allowed to dwell, producing high local antimicrobial concentrations with minimal systemic exposure. Taurolidine undergoes hydrolytic conversion to intermediate products such as taurultam and ultimately to taurine; these metabolic pathways contribute to its low propensity for selecting antibiotic resistance. Standard formulation parameters, compatibility with common catheter materials, in vitro activity against gram positive and gram negative organisms including biofilm-embedded bacteria, and reported tolerability in vascular access settings are key technical considerations for healthcare use and product development.
Parent: Taurolidine
Parent: Taurolidine
Typical quality specifications for pharmaceutical grade taurolidine include an assay by validated HPLC of 98.0 percent or greater, total related substances not exceeding 2.0 percent by area, and individual unspecified impurities limited to 0.5 percent or less by area, with stricter limits applied to known related compounds. Known related or degradant species observed during manufacture and stability testing include taurultam, methylol-taurultam species, taurinamide and increased levels of taurine as a hydrolysis product; formaldehyde-releasing fragments can be detected at trace levels during forced degradation studies. Impurity profiling relies on orthogonal methods such as HPLC with PDA detection, LC-MS for identification, and validated limits for heavy metals and residual solvents. Storage and handling that minimize moisture and heat exposure reduce conversion to degradants and help maintain assay and impurity profiles within specification.
Taurolidine is primarily used as an antimicrobial catheter lock solution to prevent catheter related bloodstream infections by killing microbes and preventing biofilm formation inside the catheter lumen. It is also under investigation in oncology research for potential antitumor effects.
Taurolidine itself does not have a broad FDA approval as an intravenous systemic drug. Some taurolidine-containing catheter lock products are marketed in Europe and other regions; availability and regulatory status vary by jurisdiction and such products may not have an FDA marketing approval in the United States.
No. TauroLock is a taurolidine-based catheter lock solution. Some product formulations combine taurolidine with citrate and in some cases with heparin depending on the marketed product and region, but TauroLock as a taurolidine product is distinct from pure heparin solutions.
TauroLock is instilled into the catheter lumen where taurolidine releases reactive methylol derivatives that chemically inactivate bacteria and bind bacterial endotoxins, preventing colonization and biofilm formation. The lock solution is left in place for a dwell period to achieve local antimicrobial effect with very limited systemic exposure.
